By Mark H. CacioppoAssociated PressAssociated PressWASHINGTON — The number of U.S. pharmaceutical stocks has reached a record high, with the Dow Jones Industrial Average reaching a record 11,921.67 points, or a gain of 8.7%, on Wednesday.
This is a milestone for the industry, with many companies still recovering from the pandemic and with the financial pressures facing companies in many industries.
The Dow Jones industrial average, which tracks the 50 largest U.N. financial markets, rose 10.7% to 21,611.17.
On Wednesday, the S&P 500, a measure of stocks that trade on Wall Street, climbed 1.6% to 2,903.17, its highest level since January.
With more than half the country still recovering, investors can expect a gradual recovery in the market, with companies on the rebound and many companies now on the ropes.
But stocks are also trading at an unprecedented pace, with more than 200 companies raising $1 billion or more in a single day.
“The stocks that are going up the fastest are going to be companies that are not really performing well,” said Richard Tofel, chief market strategist at Stifel Nicolaus.
Many companies are trading on high expectations for a new drug or a product.
For example, CVS Caremark, which is struggling to get a cure for the flu, was able to raise $2.3 billion in a record-setting $2 billion round of financing, with a market cap of $62.6 billion.
That comes on top of an earlier round of $1.9 billion it raised earlier this month.
CVS said it is now the nation’s second-largest drug company.
Another example is Pfizer, which has raised $8.9 million to date to develop a new lung cancer drug.
In fact, companies that have not been profitable for a long time, such as Pfizer and Allergan, are now surging.
Pfizer’s shares jumped more than 12% after the company announced it was raising $9.5 billion in funding, bringing its market cap to $67.9bn.
Allergan is also surging.
The drugmaker reported its first profit since 2010 on Wednesday and posted a profit of $2,637 million.
That came on top the company’s $2 trillion acquisition of Mylan.
The number and size of the new investments are outpacing the companies’ earnings growth and are making it more likely that those companies will eventually rebound.
Despite the strong market gains, some companies are struggling.
Pharmaceuticals companies are still suffering from the economic downturn and some are facing pressure from rivals, including generics makers Pfizer (PFE), Johnson & Johnson (JNJ) and AstraZeneca (AZN), which are battling for control of the market.
Even with the economic recovery, some analysts warn that the stocks could be overvalued.
Markets have fallen about 40% since the end of the financial crisis, which included the stock market crash of 2008.
Investors should also be wary of companies that do not perform as well as they did in the past.
For example, a lot of stocks have been trading at a loss and a lot have not.
A lot of the big companies are losing money.
There are some companies that look like they are going back to their good old days and a few that look pretty bad,” said Peter Korn, an analyst at the research firm CMC Markets.
To help investors understand the stocks and where to look for them, CMC has created a simple guide.
The guide shows how many shares to buy, where to buy them and how to buy on a spread basis.
If you want to buy stocks that have more than $50 billion in market cap, there are more than 80 stocks in this category.
If you want a smaller spread, the top 30 stocks in the index are worth $50.
The top 30 are worth more than the top 20.
Read more from the Reuters Consumer section:For more market coverage, visit the Reuters Web site.
Follow Reuters Consumer on Twitter at http://twitter.com/ReutersConsumer and on Facebook at http:/ /www.facebook.com/_ReutersConsumer.